Symptomtext
vaccine given to 27 weeks pregnant patient with no reported adverse event; Initial information received on 01-May-2023 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 21 years old female patient who was exposed to vaccine influenza usp trival a-b subvirion no preservative vaccine [fluzone] in context of vaccine given to 27 weeks pregnant patient with no reported adverse event. Data regarding this pregnancy were received prospectively, i.e. before pregnancy outcome was known. The reported vaccine given to 27 weeks pregnant patient with no reported adverse event occurred at 27 weeks of pregnancy and the patient was exposed to Influenza usp trival a-b subvirion no preservative vaccine at 27 weeks of pregnancy, during third pregnancy trimester for influenza usp trival a-b subvirion no preservative vaccine. The date of last menstrual period was reported as 23-Oct-2022. The estimated due date is 30-Jul-2023. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. The patient had unknown previous pregnancy/ies. On 28-Apr-2023, the patient received 0.5 ml of suspect influenza usp trival a-b subvirion no preservative vaccine Suspension for injection lot UJ906AA, 30-Jun-2023 via intramuscular route in the left deltoid for Influenza. On 28-Apr-2023 the patient developed a non-serious vaccine given to 27 weeks pregnant patient with no reported adverse event (exposure during pregnancy) (latency: same day). Relevant prenatal testing after exposure was unknown Lab data was not reported. Action taken was not applicable. Outcome: Unknown for the event vaccine given to 27 weeks pregnant patient with no reported adverse event. Additionally, at time of reporting, the pregnancy is still ongoing.